Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTime Finance Regulatory News (TIME)

Share Price Information for Time Finance (TIME)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.75 (1.66%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £42.17m
TIME Live PriceLast checked at - London Stock Exchange

Intraday Time Finance Share Chart

Contract Win & Trading Update

13 Aug 2007 07:00

Timestrip PLC13 August 2007 Timestrip plc (the 'Company') (AIM: TIME) Significant Contract Win and Trading Update The Company is a developer and manufacturer of unique label technologies. The Company is delighted to announce that it has signed a three year rollingcontract to supply the unique Timestrip technology to one of North America'sleading consumer product companies. The deal, estimated to be worth a minimum of US$3million in revenues to theCompany over the first three years, involves the integration of the Timestripinto a market leading product that is currently used in millions of homes acrossthe world. However, it is currently subject to confidentiality restrictionsrelating to the details of the product and the identity of the customer. This revenue estimate is based only on sales in North America, but theopportunity exists for significant additional revenues in the event that thetechnology is adopted by the customer on identical products that they currentlysell worldwide. This contract, which was referred to in the Company's recent preliminaryresults, is the first of several significant deals which are expected to besigned during the course of 2007. Sales cycles across large global multinationals are lengthy and it now seemslikely that the timing of these deals is such that they are not likely tocontribute materially to revenues in 2007. Accordingly, whilst the Companyexpects the revenue for the year to be above those of 2006, it now expects themto be lower than current market expectations for 2007. However, the dealsinvolve the integration of technology into established products lines and willtherefore have a recurring revenue impact into the longer term. The Company is pleased to report that it is experiencing unprecedented levels ofnew enquiries especially across the food and pharmaceutical sectors, which inturn is generating a strong sales pipeline. Interim results are expected towards the end of September at which timeShareholders will be provided with an update on the Company's continuedprogress. Enquiries: Paul Freedman/Reuben Isbitsky, Joint CEOs, Timestrip plc 01462 440 700 Shane Dolan, Biddicks 020 7448 1000 Fergus Marcroft, Evolution Securities 020 7071 4300 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th Jun 20267:00 amRNSLending Book Milestone & Notice of Q4 Update
24th Mar 20267:00 amRNSQ3 Trading Update
16th Mar 20267:00 amRNSNotice of Trading Update
16th Mar 20267:00 amRNSNotice of Trading Update
27th Jan 20267:00 amRNSInterim Results
16th Dec 20257:00 amRNSHalf-Year Trading Update & Notice of Results
19th Nov 20257:00 amRNSGrant of 2025 LTIP Awards
14th Nov 20251:57 pmRNSExercise of Options & Director/PDMR Shareholdings
12th Nov 20257:00 amRNSLoan Book Update
6th Nov 202512:07 pmRNSResult of AGM
28th Oct 20257:00 amRNSNotice of Trading Update & Investor Presentations
3rd Oct 20257:00 amRNSVesting of Option Awards
26th Sep 20257:00 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSNotice of AGM
24th Sep 20257:01 amRNSQ1 Trading Update
24th Sep 20257:00 amRNSFinal Results
18th Sep 20257:00 amRNSNotice of Results, Investor Presentation and AGM
1st Aug 20257:00 amRNSExtended Funding Facilities
26th Jun 20257:00 amRNSTrading Update and Notice of Final Results
4th Jun 20257:00 amRNSLaunch of New Investor Hub
6th May 20257:00 amRNSNotice of Q4 Trading Update and of Final Results
25th Mar 20257:00 amRNSQ3 Trading Update
12th Mar 20257:00 amRNSNotice of Investor Presentation
3rd Mar 20257:00 amRNSDirector/PDMR Shareholding
28th Feb 20257:00 amRNSDirector/PDMR Shareholding
27th Feb 202512:00 pmRNSNotice of Trading Update
11th Feb 20257:00 amRNSLending Portfolio Update
28th Jan 20257:00 amRNSInterim Results
19th Dec 20247:00 amRNSHalf-Year Trading Update & Notice of Results
22nd Nov 20249:03 amRNSHolding(s) in Company
12th Nov 20247:00 amRNSTrading Update
5th Nov 202412:30 pmRNSResult of AGM
24th Oct 20247:00 amRNSExercise of Options & Director/PDMR Shareholdings
4th Oct 20247:00 amRNSVesting of Option Awards
3rd Oct 20247:00 amRNSDirector share purchases
2nd Oct 20247:00 amRNSExtended & Improved £65m NatWest Funding Facility
26th Sep 20247:00 amRNSNotice of AGM
25th Sep 20247:01 amRNSQ1 Trading Update
25th Sep 20247:00 amRNSFinal Results
10th Sep 20247:00 amRNSNotice of Results, Investor Pres & Trading Update
27th Aug 20247:00 amRNSGrowth Guarantee Scheme Accreditation
3rd Jul 20247:00 amRNSDirector Share Purchase
27th Jun 20247:00 amRNSTrading Update and Notice of Final Results
3rd Apr 20247:00 amRNSExtended & Improved £64m Funding Facility
26th Mar 20247:00 amRNSQ3 Trading Update
5th Mar 20247:00 amRNSNotice of Trading Update
25th Jan 20247:00 amRNSInterim Results
18th Jan 20244:30 pmRNSHolding(s) in Company
19th Dec 20237:00 amRNSHalf-Year Trading Update & Notice of Results
21st Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.